Anti-HIV compounds

Abstract

The present invention provides compounds having formula (I) or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them, processes for their preparation, and methods for treating and preventing HIV infection by administration thereof. This disclosure relates to compounds for use in the treatment of Retroviridae virus infections, including infections caused by the HIV virus. This disclosure also relates to intermediates for their preparation and to pharmaceutical compositions containing these compounds. TIFF2026519482000353.tif65128

Claims

1. Compound of formula (I) 【Chemistry 251】 or a pharmaceutically acceptable salt thereof, in the formula, R １ However, the 5-10 member heterocyclyl having 1 to 5 heteroatoms selected from N, O, and S, or the 5-10 member heteroaryl having 1 to 5 heteroatoms selected from N, O, and S, wherein the 5-10 member heterocyclyl or 5-10 member heteroaryl optionally has 1 to 5 R ａ It is substituted with the base, R ２ and R ３ are each independently C １～４ alkyl, C ３～６ cycloalkyl, O-R ２Ａ , C １～２ alkyl-O-R ２Ａ , N-(R ３Ａ ), ２ or C １～２ alkyl-N-(R ３Ａ ), ２ and Each R ２Ａ However, independently, C １～４ Alkyl, C ３～６ A cycloalkyl or a 4-10 membered heterocycline having 1-5 heteroatoms selected from N, O, and S, Each R ３Ａ However, independently, hydrogen, C １～４ Alkyl, C ３～６ Cycloalkyl, or COO(R) ｅ ) and each R ｅ However, independently, hydrogen or C １～４ It is alkyl, Each C ３～６ A cycloalkyl or 4-10 membered heterocycline is optionally associated with 1-3 R groups. ｆ It is substituted by a group, and each R ｆ However, independently, C １～２ It is an alkyl or halogen, R ４ However, hydrogen, halo, C １～４ Alkyl, C １～４ Haloalkyl, C ３～６ Cycloalkyl, C １～４ Alkoxy, or C １～４ It is a haloalkoxy, R ７ However, hydrogen, halo, C １～４ Alkyl, C １～４ Haloalkyl, C ３～６ Cycloalkyl, C １～４ Alkoxy, or C １～４ It is a haloalkoxy, R ５ , R ６ , R ８ , and R ９ However, each is independent of hydrogen, halo, and C. １～２ Alkyl, C １～２ Haloalkyl, or C ３～６ It is a cycloalkyl, R ４ , R ５ , and R ６ Two or more of the above, or R ７ , R ８ , and R ９ Two or more of these are arbitrarily chosen to be combined together to form one or more C ３～６ A cycloalkyl group is formed, and the one or more C ３～６ Cycloalkyl groups can be optionally selected from halogens and C １～２ Alkyl and C １～２ It is substituted with 1 to 4 groups selected from haloalkyl groups. Each R １０ However, independently, halogen, cyano, C １～４ Alkoxy, C １～６ Alkyl, or C ３～６ It is a cycloalkyl, n is between 0 and 4, Each R ａ However, independently, halogen, C １～４ Alkyl, hydroxyl, and C １～４ A carbon atom having one or two groups selected from alkoxy groups. １～４ Alkyl, C １～４ Haloalkyl, C １～４ Alkoxy, C ３～６ A 4-10 membered heterocycline having 1-5 heteroatoms selected from cycloalkyl, N, O, and S, wherein the 4-10 membered heterocycline is optionally R ａ１ or O-R ３Ｂ It has been replaced with, R ３Ｂ However, R is optional. ａ１ C replaced by ３～６ A cycloalkyl or a 4-10 membered heterocycline having 1-5 heteroatoms selected from N, O, and S, wherein the 4-10 membered heterocycline is optionally R ａ１ It has been replaced with, Each R ａ１ However, independently, C １～４ Alkyl, C ３～６ Cycloalkyl, C １～４ A haloalkyl or a 4-8 membered heterocycline having 1-3 heteroatoms selected from N, O, and S, A is ethynyl or a bond, X １ However, it is a 6-10 membered aryl or a 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, O, and S, and each 6-10 membered aryl or 5-10 membered heteroaryl has 1-4 R atoms of optional choice. ｂ It is substituted with the base, X ２ However, the 4-10 membered heterocycline has hydrogen or 1 to 5 heteroatoms selected from N, O, and S, and the 4-10 membered heterocycline optionally has 1 R １１ It is replaced with, and you can optionally choose 1 to 5 R ｂ It is substituted with the base, R １１ is -C=O (R ｃ ), CH ２ (R ｄ ), S(O) １～２ (C １～４ alkyl), S(O) １～２ -(C ３～６ cycloalkyl), a 4 - 10 - membered heterocyclyl having 1 - 5 heteroatoms selected from N, O, and S, or a 5 - 9 - membered heteroaryl having 1 - 5 heteroatoms selected from N, O, and S, and each 4 - 10 - membered heterocyclyl or 5 - 9 - membered heteroaryl is optionally substituted with 1 - 5 R ｂ groups, Each R ｂ is independently selected from halogen, oxo, C １～４ alkyl, hydroxyl, and C １～４ alkoxy, and has 1 to 2 groups selected from these, and is C １～４ alkyl, C １～４ haloalkyl, C １～４ alkoxy, or COO(R ｅ ), and R ｃ However, C １～４ Alkyl, C １～４ Haloalkyl, C １～４ Alkoxy, N(R ｅ ) ２ , C ３～６ A cycloalkyl or a 4-6 membered heterocycline having 1-3 heteroatoms selected from N, O, and S, wherein the C ３～６ The cycloalkyl and the 4-6 membered heterocyclyl optionally have 1 to 5 R ｂ It is substituted by the group, R ｄ However, COO(R ｅ ), N (R ｅ ) ２、 C ３～６ A cycloalkyl or a 4-6 membered heterocycline having 1-3 heteroatoms selected from N, O, and S, wherein the C ３～６ The cycloalkyl and the 4-6 membered heterocyclyl optionally have 1 to 5 R ｂ It is substituted by the group, Each R １２ However, C １～２ Alkyl, Halo, -OC １～２ Alkyl or cyano, Each p is between 0 and 4, X ３ However, -C(O)O-X ４ -O- or bond, X ４ However, C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ These are alkynnyls, each of which can be optionally selected to have 1, 2, or 3 Rs. ｘ４ It has been replaced with, Each R ｘ４ However, independently, C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C １～６ Haloalkyl, -OR ２３ , -C(O)R ２３ , -C(O)OR ２３ , -C(O)N(R ２４ ) (Caution ２５ ), -OC(O)R ２３ , -OC(O)N(R ２４ ) (Caution ２５ ), -P(O)(OR ２３ ) ２ , -OP(O)(OR ２３ ) ２ , -P(O)(R ２３ ) ( OR ２３ ), or -OP(O)(R ２３ ) ( OR ２３ ) and each C １～６ Alkyl, C ２～６ Alkenyl and C ２～６ Alkinyl has 1, 2, 3, or 4 Z cells of any choice. ５ It has been replaced with, X ５ However, C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ These are alkynnyls, each of which can be optionally selected to have 1, 2, 3, or 4 Rs. ｘ５ It has been replaced with, Each R ｘ５ However, independently, C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C １～６ Haloalkyl, -OR ２３ , -C(O)R ２３ , -C(O)OR ２３ , -C(O)N(R ２４ ) (Caution ２５ ), -OC(O)R ２３ , -OC(O)N(R ２４ ) (Caution ２５ ), -P(O)(OR ２３ ) ２ , -OP(O)(OR ２３ ) ２ , -P(O)(R ２３ ) ( OR ２３ ), or -OP(O)(R ２３ ) ( OR ２３ ) and each C １～６ Alkyl, C ２～６ Alkenyl and C ２～６ Alkinyl has 1, 2, 3, or 4 Z cells of any choice. ５ It has been replaced with, ring 【Chemistry 252】 However, it is a 6-10 membered aryl or a 5-10 membered heteroaryl. Each R １４ However, independently, C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C １～６ Haloalkyl, -OR ２３ , -C(O)R ２３ , -C(O)OR ２３ , -C(O)N(R ２４ ) (Caution ２５ ), -OC(O)R ２３ , -OC(O)N(R ２４ ) (Caution ２５ ), -P(O)(OR ２３ ) ２ , -OP(O)(OR ２３ ) ２ , -P(O)(R ２３ ) ( OR ２３ ), or -OP(O)(R ２３ ) ( OR ２３ ) and each C １～６ Alkyl, C ２～６ Alkenyl and C ２～６ Alkinyl has 1, 2, 3, or 4 Z cells of any choice. ５ It has been replaced with, s is 0, 1, 2, 3, or 4, R １５ However, independently, C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C １～６ Haloalkyl, -OR ２３ , -C(O)R ２３ , -C(O)OR ２３ , -C(O)N(R ２４ ) (Caution ２５ ), -OC(O)R ２３ , -OC(O)N(R ２４ ) (Caution ２５ ), -P(O)(OR ２３ ) ２ , -OP(O)(OR ２３ ) ２ , -P(O)(R ２３ ) ( OR ２３ ), or -OP(O)(R ２３ ) ( OR ２３ ) and each C １～６ Alkyl, C ２～６ Alkenyl and C ２～６ Alkinyl has 1, 2, 3, or 4 Z cells of any choice. ５ It has been replaced with, Each R ２１ However, independently, H or C １～６ It is alkyl, each Z ５ is independently C １～６ haloalkyl, -OR ２３ , -C(O)R ２３ , -C(O)OR ２３ , -C(O)N(R ２４ )(R ２５ ), -OC(O)R ２３ , -OC(O)N(R ２４ )(R ２５ ), -P(O)(OR ２３ ), ２ , -OP(O)(OR ２３ ), ２ , -P(O)(R ２３ )(OR ２３ ), or -OP(O)(R ２３ )(OR ２３ ), and Each R ２３ However, independently, hydrogen, C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ It is an alkynyl, and each C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ Alkinyl has 1, 2, 3, or 4 Z cells of any choice. ６ It has been replaced with, Each R ２４ and R ２５ However, independently, hydrogen, C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ３～６ The compounds are cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, or 4-10 membered heterocyclyl, and each C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ３～６ Cycloalkyls, 6-10 membered aryls, 5-10 membered heteroaryls, and 4-10 membered heterocyclines are optionally associated with 1, 2, 3, or 4 Z groups. ６ It is replaced with, or R ２４ and R ２５ However, together with the nitrogen to which they are attached, they form a 4-10 membered heterocycline, and the 4-10 membered heterocycline may optionally contain 1, 2, 3, or 4 Z ６ It has been replaced with, Each Z ６ However, independently, CN, C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C １～６ Haloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, -OR ２６ , -C(O)R ２６ , -C(O)OR ２６ , -C(O)N(R ２７ ) (Caution ２８ ), -C(NOH)N(R ２７ ) (Caution ２８ ), -C(O)N(R ２６ ) S(O) ２ (R ２６ ), -C(O)N(R ２６ ) S(O) ２ N(R) ２７ ) (Caution ２８ ), -C(O)N(R ２６ ) S(O) ２ O(R) ２６ ), -OC(O)R ２６ , -OC(O)N(R ２７ ) (Caution ２８ ), -P(O)(OR ２６ ) ２ , -OP(O)(OR ２６ ) ２ , -P(O)(R ２６ ) ( OR ２６ ), -OP(O)(R ２６ ) ( OR ２６ ), -SR ２６ , -S(O)R ２６ , -S(O)(NR ２６ ) R ２６ , -S(O) ２ R ２６ , S(O) ２ OR ２６ , or -S(O) ２ N(R) ２７ ) (Caution ２８ ) or two Z ６ However, when combined, C ２～６ Alkenyls can be formed, each C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, 6-10 membered aryl, and 5-10 membered heteroaryl are optionally given 1, 2, 3, or 4 Z ７ It has been replaced with, Each Z ７ However, independently, CN, C １～６ Alkyl, C １～６ Haloalkyl, -OR ２６ , -C(O)R ２６ , -C(O)OR ２６ , -C(O)N(R ２７ ) (Caution ２８ ), -OC(O)R ２６ , -OC(O)N(R ２７ ) (Caution ２８ ), -S(O) ２ N(R) ２７ ) (Caution ２８ ), -P(O)(OR ２６ ) ２ , -OP(O)(OR ２６ ) ２ , -P(O)(R ２６ ) ( OR ２６ ), or -OP(O)(R ２６ ) ( OR ２６ ) and Each R ２６ However, independently, hydrogen, C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ It is alkinyl, Each R ２７ and R ２８ However, independently, hydrogen, C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ A compound that is alkynyl, or a pharmaceutically acceptable salt thereof.

2. R ２ and R ３ However, each is independent of C １～４ Alkyl, C ３～６ Cycloalkyl, or O-R ２Ａ And R ２Ａ However, C １～４ Alkyl, C ３～６ The compound according to claim 1 or a pharmaceutically acceptable salt thereof, which is a cycloalkyl or a 4-10 membered heterocycline having 1-5 heteroatoms selected from N, O, and S.

3. R ２ and R ３ However, each independently is as follows: the compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof. 【Chemistry 253】

4. R ２ and R ３ A compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, wherein each of the compounds is methoxy.

5. R ４ However, hydrogen, C １～４ Alkyl, or C １～４ A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, which is a haloalkyl compound.

6. R ４ However, C １～４ A compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, which is a haloalkyl compound.

7. R ４ However, CF ３ The compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof.

8. R ７ However, hydrogen, C １～４ Alkyl, or C １～４ A compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, which is a haloalkyl compound.

9. R ７ However, C １～４ A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, which is a haloalkyl compound.

10. R ７ However, CF ３ The compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof.

11. R ５ and R ６ However, C １～２ A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, which is alkyl.

12. R ５ and R ６ The compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein the compound is methyl.

13. R ８ and R ９ However, C １～２ A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, which is alkyl.

14. R ８ and R ９ The compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein the compound is methyl.

15. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, wherein n is 2.

16. Each R １０ A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein the compound is a halogen.

17. Each R １０ A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein the compound is fluoro.

18. A is ethinyl, the compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof.

19. R １ However, the 5-6 member heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S, or the 5-6 member heteroaryl having 1 to 3 heteroatoms selected from N, O, and S, wherein the 5-6 member heterocyclyl or 5-6 member heteroaryl optionally has 1 to 3 R ａ A compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

20. R １ However, it is a 5-6 membered heteroaryl having 1-3 heteroatoms selected from N, O, and S, and optionally 1-3 R ａ A compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

21. R １ However, independently, the compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof is as follows: 【Chemistry 254】

22. R １ but, 【Chemistry 255】 The compound according to any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof.

23. R ａ However, C １～４ A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, which is a haloalkyl compound.

24. R ａ but, 【Chemistry 256】 The compound according to any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof.

25. X １ However, it is a 6-membered aryl or a 5-6 membered heteroaryl having 1 to 3 heteroatoms selected from N, O, and S, and each 6-membered aryl or 5-6 membered heteroaryl has optionally 1 to 4 R ｂ A compound according to any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

26. X １ but, 【Chemistry 257】 The compound according to any one of claims 1 to 25 or a pharmaceutically acceptable salt thereof.

27. X １ but, 【Chemistry 258】 The compound according to any one of claims 1 to 26 or a pharmaceutically acceptable salt thereof.

28. X ２ However, it is a 4- to 10-membered heterocycline having 1 to 3 heteroatoms selected from N, O, and S, and optionally one R １１ It is replaced with, and you can optionally choose 1 to 5 R ｂ A compound according to any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, which is substituted with a group.

29. X ２ However, the compound according to any one of claims 1 to 28 or a pharmaceutically acceptable salt thereof is as follows: 【Chemistry 259】

30. X ２ but, 【Chemistry 260】 The compound according to any one of claims 1 to 29 or a pharmaceutically acceptable salt thereof.

31. R １１ The compound according to any one of claims 1 to 30 or a pharmaceutically acceptable salt thereof, wherein the compound is a 4- to 10-membered heterocycline having 1 to 3 heteroatoms selected from N, O, and S.

32. R １１ The compound according to any one of claims 1 to 31 or a pharmaceutically acceptable salt thereof, wherein the compound is a 4- to 6-membered heterocycline having one oxygen atom.

33. R １１ The compound according to any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, wherein the compound is oxetan-3-yl.

34. A compound according to any one of claims 1 to 33 or a pharmaceutically acceptable salt thereof, wherein p is 0.

35. Formula (II) 【Chemistry 261】 The compound according to claim 1, or having a pharmaceutically acceptable salt thereof, wherein Q is N or CH.

36. The compound according to claim 1, having formula (III). 【Chemistry 262】

37. X ３ However, -C(O)O-X ４ A compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein the compound is -O-.

38. X ４ However, you can choose one, two, or three Rs. ｘ４ C replaced by １～６ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, which is alkyl.

39. X ４ However, one or two Rs can be optionally selected. ｘ４ C replaced by １～３ A compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, which is alkyl.

40. Each R ｘ４ However, independently, one, two, three, or four Zs can be arbitrarily selected. ５ C replaced by １～６ A compound according to any one of claims 1 to 39, or a pharmaceutically acceptable salt thereof, which is alkyl.

41. X ３ The compound according to any one of claims 1 to 36 or a pharmaceutically acceptable salt thereof, wherein the compound is bonded.

42. X ５ However, you can choose 1, 2, 3, or 4 Rs. ｘ５ C replaced by １～６ A compound according to any one of claims 1 to 41, or a pharmaceutically acceptable salt thereof, which is alkyl.

43. X ５ However, one or two Rs can be optionally selected. ｘ５ C replaced by １～３ A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, which is alkyl.

44. ring 【Chemical 263】 The compound according to any one of claims 1 to 43 or a pharmaceutically acceptable salt thereof, wherein the compound is a 6-membered aryl or a 5-6 membered heteroaryl, and s is 0, 1, 2, 3, or 4.

45. ring 【Chemistry 264】 The compound according to any one of claims 1 to 44 or a pharmaceutically acceptable salt thereof, wherein the compound is a six-membered aryl compound and s is 0, 1, 2, or 3.

46. ring 【Chemical 265】 The compound according to any one of claims 1 to 44 or a pharmaceutically acceptable salt thereof, wherein the compound is a 5-6 member heteroaryl and s is 0, 1, or 2.

47. Formula (IV) 【Chemical Formula 266】 or having a pharmaceutically acceptable salt thereof, in the formula, The compound according to any one of claims 1 to 41, wherein q is 0, 1, or 2.

48. Formula (V) 【Chemistry 267】 or having a pharmaceutically acceptable salt thereof, in the formula, The compound according to any one of claims 1 to 41, wherein q is 0, 1, or 2.

49. The compound according to claim 47 or 48, or a pharmaceutically acceptable salt thereof, wherein q is 2.

50. A compound according to any one of claims 1 to 49 or a pharmaceutically acceptable salt thereof, wherein s is 0.

51. A compound according to any one of claims 1 to 49 or a pharmaceutically acceptable salt thereof, wherein s is 1.

52. Equation (VI) 【Chemical 268】 The compound according to any one of claims 1 to 48, or having a pharmaceutically acceptable salt thereof.

53. Formula (VII) 【Chemistry 269】 The compound according to any one of claims 1 to 48, or having a pharmaceutically acceptable salt thereof.

54. Each R ｘ５ However, independently, C １～６ Alkyl, C ２～６ Alkenil, C １～６ Haloalkyl, or -OR ２３ And each C １～６ Alkyl and C ２～６ Alkenil has 1, 2, 3, or 4 Zs of any choice. ５ A compound according to any one of claims 1 to 53, or a pharmaceutically acceptable salt thereof, which is substituted with.

55. Each R ｘ５ However, independently, one or two Z can be chosen at will. ５ C replaced by １～３ A compound according to any one of claims 1 to 54, or a pharmaceutically acceptable salt thereof, which is alkyl.

56. Each R ｘ５ The compound according to any one of claims 1 to 55, or a pharmaceutically acceptable salt thereof, wherein the compound is methyl.

57. R １５ However, -C(O)OR ２３ The compound according to any one of claims 1 to 56 or a pharmaceutically acceptable salt thereof.

58. R １５ However, C １～６ Alkyl, C ２～６ Alkenil, C １～６ Haloalkyl, -C(O)R ２３ , -C(O)OR ２３ , or -C(O)N(R ２４ ) (Caution ２５ ) and each C １～６ Alkyl and C ２～６ Alkenil has 1, 2, 3, or 4 Zs of any choice. ５ A compound according to any one of claims 1 to 56, or a pharmaceutically acceptable salt thereof, which is substituted with.

59. R １５ However, C １～６ Alkyl or C ２～６ They are alkenils, each of which can optionally contain one or two Z ５ A compound according to any one of claims 1 to 56 and 58, or a pharmaceutically acceptable salt thereof, which is substituted with.

60. R １５ However, one Z ５ C replaced by １～３ A compound according to any one of claims 1 to 56, 58, and 59, or a pharmaceutically acceptable salt thereof, which is alkyl.

61. Formula (VIII) 【Chemistry 270】 The compound according to any one of claims 1 to 41, or having a pharmaceutically acceptable salt thereof.

62. Formula (IX) 【Chemistry 271】 The compound according to any one of claims 1 to 41, or having a pharmaceutically acceptable salt thereof.

63. Z ５ However, independently, -C(O)OR ２３ or -C(O)N(R ２４ ) (Caution ２５ A compound according to any one of claims 1 to 61 or a pharmaceutically acceptable salt thereof.

64. Z ５ However, -C(O)N(R ２４ ) (Caution ２５ A compound according to any one of claims 1 to 62 or a pharmaceutically acceptable salt thereof.

65. Formula (X) 【Chemistry 272】 or having a pharmaceutically acceptable salt thereof, in the formula, The compound according to claim 1, wherein Q is N or CH.

66. R ２ and R ３ However, each is independent of C １～４ Alkyl, C ３～６ Cycloalkyl, or O-R ２Ａ And R ２Ａ However, C １～４ Alkyl, C ３～６ The compound according to claim 65 or a pharmaceutically acceptable salt thereof, which is a cycloalkyl or a 4-10 membered heterocycline having 1-5 heteroatoms selected from N, O, and S.

67. R ２ and R ３ However, each operates independently. 【Chemistry 273】 The compound according to claim 65 or a pharmaceutically acceptable salt thereof.

68. R ２ and R ３ The compound according to claim 65 or a pharmaceutically acceptable salt thereof, wherein each of the compounds is methoxy.

69. Formula (XI) 【Chemistry 274】 The compound according to claim 1, or having a pharmaceutically acceptable salt thereof.

70. Each R ２１ The compound according to any one of claims 1 to 69, or a pharmaceutically acceptable salt thereof, wherein the compound is hydrogen.

71. Each R １４ However, independently, C １～６ Alkyl, C ２～６ Alkenil, C １～６ Haloalkyl, -C(O)R ２３ , -C(O)OR ２３ , or -C(O)N(R ２４ ) (Caution ２５ ) and each C １～６ The alkyl group has 1, 2, 3, or 4 Z atoms of any choice. ５ A compound according to any one of claims 1 to 70 or a pharmaceutically acceptable salt thereof, which is substituted with.

72. Each R １４ However, independently, C １～６ Alkyl or -C(O)OR ２３ And each C １～６ The alkyl group has 1, 2, 3, or 4 Z atoms of any choice. ５ A compound according to any one of claims 1 to 71, or a pharmaceutically acceptable salt thereof, which is substituted with.

73. Each R ２３ However, independently, hydrogen or C １～６ It is alkyl, and each C １～６ The alkyl group has 1, 2, 3, or 4 Z atoms of any choice. ６ A compound according to any one of claims 1 to 72, or a pharmaceutically acceptable salt thereof, which is substituted with.

74. Each R ２４ and R ２５ However, independently, hydrogen, C １～６ Alkyl, aryl, or heteroaryl, each C １～６ Alkyl, aryl, and heteroaryl elements are optionally present in 1, 2, 3, or 4 Z groups. ６ It is replaced with, or R ２４ and R ２５ However, together with the nitrogen to which they are attached, they form a 4-10 membered heterocycline, and the 4-10 membered heterocycline may optionally contain 1, 2, 3, or 4 Z ６ A compound according to any one of claims 1 to 73, or a pharmaceutically acceptable salt thereof, which is substituted with.

75. Each R ２４ and R ２５ However, independently, hydrogen, or optionally one or two Z ６ C replaced by １～６ A compound according to any one of claims 1 to 74, or a pharmaceutically acceptable salt thereof, which is alkyl.

76. Each R ２４ and R ２５ However, independently, they are hydrogen, a 6-membered aryl, or a 5-6 membered heteroaryl, each of which can be optionally selected to have 1 or 2 Z ６ A compound according to any one of claims 1 to 74 or a pharmaceutically acceptable salt thereof, which is substituted with.

77. Each R ２４ and R ２５ However, together with the nitrogen to which they are attached, they form a 5-6 member heterocycline, and the 5-6 member heterocycline optionally contains 1 or 2 Z ６ A compound according to any one of claims 1 to 74 or a pharmaceutically acceptable salt thereof, which is substituted with.

78. Each Z ６ However, independently, C １～６ Alkyl, -C(O)OR ２６ , -C(O)N(R ２７ ) (Caution ２８ ), -C(NOH)N(R ２７ ) (Caution ２８ ), -C(O)N(R ２６ ) S(O) ２ (R ２６ ), -C(O)N(R ２６ ) S(O) ２ N(R) ２７ ) (Caution ２８ ), -C(O)N(R ２６ ) S(O) ２ O(R) ２６ ), -P(O)(OR ２６ )2, -OP(O)(OR ２６ )2, -P(O)(R ２６ ) ( OR ２６ ), -OP(O)(R26)(OR ２６ ), -S(O) ２ R ２６ , S(O)2OR ２６ , or -S(O) ２ N(R) ２７ ) (Caution ２８ ) and each C １～６ The alkyl group optionally contains one or two Z ７ A compound according to any one of claims 1 to 77, or a pharmaceutically acceptable salt thereof, which is substituted with.

79. Each Z ６ However, independently, C １～６ Alkyl, -C(O)OR ２６ , -C(O)N(R ２７ ) (Caution ２８ ), -C(NOH)N(R ２７ ) (Caution ２８ ), -C(O)N(R ２６ ) S(O) ２ (R ２６ ), -P(O)(OR ２６ ) ２ , -OP(O)(OR ２６ ) ２ , -S(O) ２ R ２６ , S(O) ２ OR26, or -S(O) ２ N(R) ２７ ) (Caution ２８ ) and each C １～６ The alkyl group optionally contains one or two Z ７ A compound according to any one of claims 1 to 78 or a pharmaceutically acceptable salt thereof, which is substituted with.

80. Each Z ６ However, independently, -C(O)OR ２６ or -S(O) ２ OR ２６ The compound according to any one of claims 1 to 79 or a pharmaceutically acceptable salt thereof.

81. Each Z ６ However, independently, -C(O)OR ２６ The compound according to any one of claims 1 to 80 or a pharmaceutically acceptable salt thereof.

82. Each Z ７ However, independently, -C(O)R ２６ , -C(O)OR ２６ , or -C(O)N(R ２７ ) (Caution ２８ A compound according to any one of claims 1 to 81 or a pharmaceutically acceptable salt thereof.

83. Each Z ７ However, independently, -C(O)OR ２６ The compound according to any one of claims 1 to 81 or a pharmaceutically acceptable salt thereof. 【Request Item 84】 【Table 7-1】 Table 7-2 Table 7-3 Table 7-4 Table 7-5 Table 7-6 Table 7-7 Table 7-8 Table 7-9 Table 7-10 Table 7-11 Table 7-12 Table 7-13 Table 7-14 Table 7-15 Table 7-16 Table 7-17 Table 7-18 Table 7-19 Table 7-20 Table 7-21 Table 7-22 Table 7-23 Table 7-24 Table 7-25 Table 7-26 Table 7-27 Table 7-28 Table 7-29 Table 7-30 Table 7-31 Table 7-32 Table 7-33 Table 7-34 Table 7-35 Table 7-36 Table 7-37 Table 7-38 Table 7-39 The compound according to claim 1, or selected from pharmaceutically acceptable salts thereof. 【Request Item 85】 【Chemistry 275】 The compound according to claim 1, or selected from pharmaceutically acceptable salts thereof.

86. X ３ However, it is a combination, X ５ However, C １～６ They are alkyl groups, each of which can optionally contain 1, 2, 3, or 4 R atoms. ｘ５ It has been replaced with, Each R ｘ５ However, independently, C １～６ Alkyl, C ２～６ Alkenil, C １～６ Haloalkyl, or -OR ２３ And each C １～６ Alkyl and C ２～６ Alkenil has 1, 2, 3, or 4 Zs of any choice. ５ It has been replaced with, ring 【Chemistry 276】 However, it is a 6-membered aryl or a 5-6 membered heteroaryl. Each R １４ However, independently, C １～６ Alkyl, C ２～６ Alkenil, C １～６ Haloalkyl, -OR ２３ , -C(O)R ２３ , -C(O)OR ２３ , or -C(O)N(R ２４ ) (Caution ２５ ) and each C １～６ Alkyl and C ２～６ Alkenil has 1, 2, 3, or 4 Zs of any choice. ５ It has been replaced with, s is 0, 1, 2, or 3, R １５ However, independently, C １～６ Alkyl, C ２～６ Alkenil, C １～６ Haloalkyl, -C(O)R ２３ , or -C(O)N(R ２４ ) (Caution ２５ ) and each C １～６ Alkyl and C ２～６ Alkenil has 1, 2, 3, or 4 Zs of any choice. ５ It has been replaced with, Each R ２１ However, independently, H or C １～６ It is alkyl, Each Z ５ However, independently, -C(O)OR ２３ or -C(O)N(R ２４ ) (Caution ２５ ) and Each R ２３ However, independently, hydrogen or C １～６ It is alkyl, and each C １～６ The alkyl group has 1, 2, 3, or 4 Z atoms of any choice. ６ It has been replaced with, Each R ２４ and R ２５ However, independently, hydrogen, C １～６ Alkyl, 6-10 membered aryl, or 5-10 membered heteroaryl, each C １～６ Alkyl, 6-10 membered aryl, or 5-10 membered heteroaryl, optionally with 1, 2, 3, or 4 Z groups. ６ It is replaced with, or R ２４ and R ２５ However, together with the nitrogen to which they are attached, they form a 4-10 membered heterocycline, and the 4-10 membered heterocycline may optionally contain 1, 2, 3, or 4 Z ６ It has been replaced with, Each Z ６ However, independently, C １～６ Alkyl, -C(O)R ２６ , -C(O)OR ２６ , -C(O)N(R ２７ ) (Caution ２８ ), -C(NOH)N(R ２７ ) (Caution ２８ ), -C(O)N(R ２６ ) S(O) ２ (R ２６ ), -C(O)N(R ２６ ) S(O) ２ N(R) ２７ ) (Caution ２８ ), -C(O)N(R ２６ ) S(O) ２ O(R) ２６ ), -P(O)(OR ２６ ) ２ , -OP(O)(OR ２６ ) ２ , -P(O)(R ２６ ) ( OR ２６ ), -OP(O)(R ２６ ) ( OR ２６ ), -S(O) ２ R ２６ , S(O) ２ OR ２６ , or -S(O) ２ N(R) ２７ ) (Caution ２８ ) and each C １～６ The alkyl group has 1, 2, 3, or 4 Z atoms of any choice. ７ It has been replaced with, Each Z ７ However, independently, -C(O)R ２６ , -C(O)OR ２６ , or -C(O)N(R ２７ ) (Caution ２８ ) and Each R ２６ However, independently, hydrogen, C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ It is alkinyl, Each R ２７ and R ２８ However, independently, hydrogen, C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ A compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, which is an alkynyl.

87. X ３ However, it is a combination, 【Chemistry 277】 but, 【Chemistry 278】 And, R １４ However, independently, C １～６ Alkyl, C ２～６ Alkenil, C １～６ Haloalkyl, -C(O)R ２３ , -C(O)OR ２３ , or -C(O)N(R ２４ ) (Caution ２５ ) and each C １～６ Alkyl and C ２～６ Alkenil has 1, 2, 3, or 4 Zs of any choice. ５ It has been replaced with, Each R ２１ However, independently, H or C １～４ It is alkyl, Each Z ５ However, independently, -C(O)OR ２３ or -C(O)N(R ２４ ) (Caution ２５ ) and Each R ２３ However, independently, hydrogen or C １～６ It is alkyl, and each C １～６ The alkyl group has 1, 2, 3, or 4 Z atoms of any choice. ６ It has been replaced with, Each R ２４ and R ２５ However, independently, hydrogen, C １～６ Alkyl, 6-10 membered aryl, or 5-10 membered heteroaryl, each C １～６ Alkyl, 6-10 membered aryl, or 5-10 membered heteroaryl, optionally with 1, 2, 3, or 4 Z groups. ６ It is replaced with, or R ２４ and R ２５ However, together with the nitrogen to which they are attached, they form a 4-10 membered heterocycline, and the 4-10 membered heterocycline may optionally contain 1, 2, 3, or 4 Z ６ It has been replaced with, Each Z ６ However, independently, C １～６ Alkyl, -C(O)R ２６ , -C(O)OR ２６ , -C(O)N(R ２７ ) (Caution ２８ ), -C(NOH)N(R ２７ ) (Caution ２８ ), -C(O)N(R ２６ ) S(O) ２ (R ２６ ), -C(O)N(R ２６ ) S(O) ２ N(R) ２７ ) (Caution ２８ ), -C(O)N(R ２６ ) S(O) ２ O(R) ２６ ), -P(O)(OR ２６ ) ２ , -OP(O)(OR ２６ ) ２ , -P(O)(R ２６ ) ( OR ２６ ), -OP(O)(R ２６ ) ( OR ２６ ), -S(O) ２ R ２６ , S(O) ２ OR ２６ , or -S(O) ２ N(R) ２７ ) (Caution ２８ ) and each C １～６ The alkyl group has 1, 2, 3, or 4 Z atoms of any choice. ７ It has been replaced with, Each Z ７ However, independently, -C(O)R ２６ , -C(O)OR ２６ , or -C(O)N(R ２７ ) (Caution ２８ ) and Each R ２６ However, independently, hydrogen, C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ It is alkinyl, Each R ２７ and R ２８ However, independently, hydrogen, C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ A compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, which is an alkynyl.

88. X ３ However, it is a combination, Each R ｘ５ However, you can choose one or two Z ５ Replaced with C １～４ It is alkyl, q is 1 or 2, 【Chemistry 279】 but, 【Chemistry 280】 And, Each R １４ However, independently, C １～６ Alkyl or -C(O)OR ２３ And each C １～６ The alkyl group has 1, 2, 3, or 4 Z atoms of any choice. ５ It has been replaced with, s is 0, 1, 2, or 3, R １５ However, C １～６ Alkyl or C ２～６ They are alkenils, each of which can optionally contain one or two Z ５ It has been replaced with, Each R ２１ However, independently, H or C １～４ It is alkyl, Each Z ５ However, independently, -C(O)OR ２３ or -C(O)N(R ２４ ) (Caution ２５ ) and Each R ２３ However, independently, hydrogen or C １～６ It is alkyl, and each C １～６ The alkyl group has 1, 2, 3, or 4 Z atoms of any choice. ６ It has been replaced with, Each R ２４ and R ２５ However, independently, hydrogen, C １～６ Alkyl, 6-10 membered aryl, or 5-10 membered heteroaryl, each C １～６ Alkyl, 6-10 membered aryl, or 5-10 membered heteroaryl, optionally with 1, 2, 3, or 4 Z groups. ６ It is replaced with, or R ２４ and R ２５ However, together with the nitrogen to which they are attached, they form a 4-10 membered heterocycline, and the 4-10 membered heterocycline may optionally contain 1, 2, 3, or 4 Z ６ It has been replaced with, Each Z ６ However, independently, C １～６ Alkyl, -C(O)R ２６ , -C(O)N(R ２７ ) (Caution ２８ ), -C(NOH)N(R ２７ ) (Caution ２８ ), -C(O)N(R ２６ ) S(O) ２ (R ２６ ), -P(O)(OR ２６ ) ２ , -OP(O)(OR ２６ ) ２ , -P(O)(R ２６ ) ( OR ２６ ), -S(O) ２ R ２６ , S(O) ２ OR ２６ , or -S(O) ２ N(R) ２７ ) (Caution ２８ ) and each C １～６ The alkyl group optionally contains one or two Z ７ It has been replaced with, Each Z ７ However, -C(O)OR ２６ And, Each R ２６ However, independently, hydrogen, C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ It is alkinyl, Each R ２７ and R ２８ However, independently, hydrogen, C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ A compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, which is an alkynyl.

89. X ３ However, it is a combination, 【Chemistry 281】 but, 【Chemistry 282】 And, Each R １４ However, independently, C １～６ Alkyl or -C(O)OR ２３ And each C １～６ The alkyl group has 1, 2, 3, or 4 Z atoms of any choice. ５ It has been replaced with, Each R ２１ However, independently, H or C １～４ It is alkyl, Each Z ５ However, independently, -C(O)OR ２３ or -C(O)N(R ２４ ) (Caution ２５ ) and Each R ２３ However, independently, hydrogen or C １～６ It is alkyl, and each C １～６ The alkyl group has 1, 2, 3, or 4 Z atoms of any choice. ６ It has been replaced with, Each R ２４ and R ２５ However, independently, hydrogen, C １～６ Alkyl, 6-10 membered aryl, or 5-10 membered heteroaryl, each C １～６ Alkyl, 6-10 membered aryl, or 5-10 membered heteroaryl, optionally with 1, 2, 3, or 4 Z groups. ６ It is replaced with, or R ２４ and R ２５ However, together with the nitrogen to which they are attached, they form a 4-10 membered heterocycline, and the 4-10 membered heterocycline may optionally contain 1, 2, 3, or 4 Z ６ It has been replaced with, Each Z ６ However, independently, C １～６ Alkyl, -C(O)R ２６ , -C(O)OR ２６ , -C(O)N(R ２７ ) (Caution ２８ ), -C(NOH)N(R ２７ ) (Caution ２８ ), -C(O)N(R ２６ ) S(O) ２ (R ２６ ), -P(O)(OR ２６ ) ２ , -OP(O)(OR ２６ ) ２ , -P(O)(R ２６ ) ( OR ２６ ), -S(O) ２ R ２６ , S(O) ２ OR ２６ , or -S(O) ２ N(R) ２７ ) (Caution ２８ ) and each C １～６ The alkyl group optionally contains one or two Z ７ It has been replaced with, Each Z ７ However, -C(O)OR ２６ And, Each R ２６ However, independently, hydrogen, C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ It is alkinyl, Each R ２７ and R ２８ However, independently, hydrogen, C １～６ Alkyl, C ２～６ Alkenyl, or C ２～６ A compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, which is an alkynyl.

90. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 89 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

91. The pharmaceutical composition according to claim 90, further comprising 1, 2, 3, or 4 additional therapeutic agents.

92. The aforementioned 1, 2, 3, or 4 additional therapeutic agents include: combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, HIV capsid inhibitors, nucleocapsid protein 7 (NCp7) inhibitors, and HIV Tat or Rev inhibitors, Tat-TAR-P-TEFb inhibitors, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editors (e.g., CRISPR / Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALEN), cell therapies (e.g., chimeric antigen receptor T cells, CAR-T, and engineered T cell receptors, TCR-T, autologous T cell therapy, engineered B cells, NK cells), latent infection reactivators, immune-based therapies, phosphatidylinositol 3 kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and "antibody-like" therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitors, fatty acid synthase inhibitors, HIV vif gene modulators, vif dimerization antagonists, HIV-1 virus infectivity factor inhibitors, HIV-1 Nef modulators, TNF alpha-ligand inhibitors, HIV Nef inhibitors, Hck tyrosine kinase modulators, mixed-lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain-containing protein 1 modulators, HIV ribonuclease H inhibitors, IFN antagonists, retrocyclin modulators, CD3 antagonists, CDK-4 inhibitors, CDK-6 inhibitors, CDK-9 inhibitors, cytochrome P450 3 inhibitors, CXCR4 modulators, dendritic cell ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIVThe pharmaceutical composition according to claim 91, selected from the group consisting of a POL protein inhibitor, a complement factor H modulator, a ubiquitin ligase inhibitor, a deoxycytidine kinase inhibitor, a cyclin-dependent kinase inhibitor, an HPK1 (MAP4K1) inhibitor, a proprotein converter PC9 stimulant, an ATP-dependent RNA helicase DDX3X inhibitor, a reverse transcriptase priming complex inhibitor, a G6PD and NADH oxidase inhibitor, an mTOR complex 1 inhibitor, an mTOR complex 2 inhibitor, a P-glycoprotein modulator, an RNA polymerase modulator, a TAT protein inhibitor, a prolyl endopeptidase inhibitor, a phospholipase A2 inhibitor, a pharmacokinetic enhancer, an HIV gene therapy, an HIV vaccine, and an anti-HIV peptide, or any combination thereof.

93. The pharmaceutical composition according to claim 91, wherein the 1, 2, 3, or 4 additional therapeutic agents are selected from the group consisting of a combination drug for HIV, another drug for treating HIV, an HIV protease inhibitor, an HIV reverse transcriptase inhibitor, an HIV integrase inhibitor, an HIV non-catalytic (or allosteric) integrase inhibitor, an HIV entry (fusion) inhibitor, an HIV maturation inhibitor, a latent infection reactivator, a capsid inhibitor, an immune-based therapy, a PI3K inhibitor, an HIV antibody, a bispecific antibody, an "antibody-like" therapeutic protein, or any combination thereof.

94. The pharmaceutical composition according to any one of claims 91 to 93, wherein the 1, 2, 3, or 4 additional therapeutic agent is selected from the group consisting of dolutegravir, cabotegravir, darunavir, bictegravir, el-sulfavirine, rilpivirine, abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemi-fumarate, tenofovir alafenamide, and tenofovir alafenamide hemi-fumarate, or pharmaceutically acceptable salts thereof.

95. The pharmaceutical composition according to any one of claims 91 to 94, wherein the 1, 2, 3, or 4 additional therapeutic agents are selected from abacavir sulfate, bictegravir, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide, tenofovir alafenamide fumarate, and tenofovir alafenamide hemifumarate.

96. The pharmaceutical composition according to any one of claims 91 to 95, wherein the 1, 2, 3, or 4 additional therapeutic agents are selected from tenofovir alafenamide, tenofovir alafenamide fumarate, and tenofovir alafenamide hemifumarate.

97. The pharmaceutical composition according to any one of claims 91 to 94, wherein the 1, 2, 3, or 4 additional therapeutic agents are selected from bictegravir, emtricitabine, and GS-9131.

98. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 283】 A pharmaceutical composition according to any one of claims 91 to 94, or selected from pharmaceutically acceptable salts thereof.

99. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 284】 A pharmaceutical composition according to any one of claims 91 to 94 and 98, or selected from pharmaceutically acceptable salts thereof.

100. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemical 285】 A pharmaceutical composition according to any one of claims 91 to 94, 98, and 99, or a pharmaceutically acceptable salt thereof.

101. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 286】 A pharmaceutical composition according to any one of claims 91 to 94, 98, and 99, or a pharmaceutically acceptable salt thereof.

102. A method for treating or preventing human immunodeficiency virus (HIV) infection in a patient who requires such treatment, comprising administering to the patient, to the subject requiring such treatment, a therapeutically effective amount of a compound according to any one of claims 1 to 89 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 90 to 101.

103. A method for treating human immunodeficiency virus (HIV) infection in a patient who has undergone severe treatment, comprising administering to the patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 89, or a pharmaceutically acceptable composition according to any one of claims 90 to 101.

104. The method according to claim 102 or 103, wherein the method comprises administering the compound or a pharmaceutically acceptable salt thereof in combination with one, two, three, or four additional therapeutic agents.

105. The aforementioned 1, 2, 3, or 4 additional therapeutic agents include: combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, HIV capsid inhibitors, nucleocapsid protein 7 (NCp7) inhibitors, and HIV Tat or Rev inhibitors, Tat-TAR-P-TEFb inhibitors, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editors (e.g., CRISPR / Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALEN), cell therapies (e.g., chimeric antigen receptor T cells, CAR-T, and engineered T cell receptors, TCR-T, autologous T cell therapy, engineered B cells, NK cells), latent infection reactivators, immune-based therapies, phosphatidylinositol 3 kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and "antibody-like" therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitors, fatty acid synthase inhibitors, HIV vif gene modulators, vif dimerization antagonists, HIV-1 virus infectivity factor inhibitors, HIV-1 Nef modulators, TNF alpha-ligand inhibitors, HIV Nef inhibitors, Hck tyrosine kinase modulators, mixed-lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain-containing protein 1 modulators, HIV ribonuclease H inhibitors, IFN antagonists, retrocyclin modulators, CD3 antagonists, CDK-4 inhibitors, CDK-6 inhibitors, CDK-9 inhibitors, cytochrome P450 3 inhibitors, CXCR4 modulators, dendritic cell ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIVThe method according to claim 104, comprising a POL protein inhibitor, a complement factor H modulator, a ubiquitin ligase inhibitor, a deoxycytidine kinase inhibitor, a cyclin-dependent kinase inhibitor, an HPK1 (MAP4K1) inhibitor, a proprotein converter PC9 stimulant, an ATP-dependent RNA helicase DDX3X inhibitor, a reverse transcriptase priming complex inhibitor, a G6PD and NADH oxidase inhibitor, an mTOR complex 1 inhibitor, an mTOR complex 2 inhibitor, a P-glycoprotein modulator, an RNA polymerase modulator, a TAT protein inhibitor, a prolyl endopeptidase inhibitor, a phospholipase A2 inhibitor, a pharmacokinetic enhancer, an HIV gene therapy, an HIV vaccine, and an anti-HIV peptide, or any combination thereof.

106. The method according to claim 104 or 105, wherein the 1, 2, 3, or 4 additional therapeutic agents are selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalyzed (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latent infection reactivators, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies, bispecific antibodies, and "antibody-like" therapeutic proteins, or any combination thereof.

107. The method according to any one of claims 104 to 106, wherein the 1, 2, 3, or 4 additional therapeutic agent is selected from the group consisting of dolutegravir, cabotegravir, darunavir, bictegravir, el-sulfavirine, rilpivirine, abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemi-fumarate, tenofovir alafenamide, and tenofovir alafenamide hemi-fumarate, or pharmaceutically acceptable salts thereof.

108. The method according to any one of claims 104 to 107, wherein the 1, 2, 3, or 4 additional therapeutic agents are selected from abacavir sulfate, bictegravir, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide, tenofovir alafenamide fumarate, and tenofovir alafenamide hemifumarate.

109. The method according to any one of claims 104 to 108, wherein the 1, 2, 3, or 4 additional therapeutic agents are selected from tenofovir alafenamide, tenofovir alafenamide fumarate, and tenofovir alafenamide hemifumarate.

110. The method according to any one of claims 104 to 106, wherein the 1, 2, 3, or 4 additional therapeutic agents are selected from bictegravir, emtricitabine, and GS-9131.

111. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 287】 Or the method according to any one of claims 104 to 106, selected from pharmaceutically acceptable salts thereof.

112. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemical 288】 Or the method according to any one of claims 104 to 106 and 111, selected from pharmaceutically acceptable salts thereof.

113. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 289】 The method according to any one of claims 104 to 106, 111, and 112, or a pharmaceutically acceptable salt thereof.

114. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 290】 The method according to any one of claims 104 to 106, 111, and 112, or a pharmaceutically acceptable salt thereof.

115. The method according to any one of claims 102 to 114, wherein the patient is a human being.

116. A therapeutically effective amount of a compound according to any one of claims 1 to 89 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 90 to 101, for use in therapy.

117. A compound or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition, for use in a method of treating or preventing human immunodeficiency virus (HIV) infection in a patient who requires such treatment or prevention, wherein the method comprises administering a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof, or the pharmaceutically acceptable composition, to the patient or subject requiring such treatment or prevention.

118. A compound or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof, for use in a method for treating human immunodeficiency virus (HIV) infection in a patient who has experienced severe treatment, wherein the method comprises administering to the patient a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof, or the pharmaceutically acceptable composition.

119. The compound for use according to claim 117 or 118, further comprising administering a therapeutically effective amount of one, two, three, or four additional therapeutic agents or pharmaceutically acceptable salts thereof.

120. The compound for use according to claim 119, wherein the additional therapeutic agent is administered simultaneously with the compound or a pharmaceutically acceptable salt thereof.

121. The compound for use according to claim 119, wherein the compound or a pharmaceutically acceptable salt thereof is combined with the additional therapeutic agent in a unit dosage form for co-administration.

122. The compound for use according to claim 119, wherein the compound or a pharmaceutically acceptable salt thereof and the additional therapeutic agent are administered sequentially.

123. The aforementioned 1, 2, 3, or 4 additional therapeutic agents include: combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, HIV capsid inhibitors, nucleocapsid protein 7 (NCp7) inhibitors, and HIV Tat or Rev inhibitors, Tat-TAR-P-TEFb inhibitors, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editors (e.g., CRISPR / Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALEN), cell therapies (e.g., chimeric antigen receptor T cells, CAR-T, and engineered T cell receptors, TCR-T, autologous T cell therapy, engineered B cells, NK cells), latent infection reactivators, immune-based therapies, phosphatidylinositol 3 kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and "antibody-like" therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitors, fatty acid synthase inhibitors, HIV vif gene modulators, vif dimerization antagonists, HIV-1 virus infectivity factor inhibitors, HIV-1 Nef modulators, TNF alpha-ligand inhibitors, HIV Nef inhibitors, Hck tyrosine kinase modulators, mixed-lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain-containing protein 1 modulators, HIV ribonuclease H inhibitors, IFN antagonists, retrocyclin modulators, CD3 antagonists, CDK-4 inhibitors, CDK-6 inhibitors, CDK-9 inhibitors, cytochrome P450 3 inhibitors, CXCR4 modulators, dendritic cell ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIVCompounds for use according to any one of claims 119 to 122, selected from the group consisting of POL protein inhibitors, complement factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin-dependent kinase inhibitors, HPK1 (MAP4K1) inhibitors, proprotein converter PC9 stimulants, ATP-dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH oxidase inhibitors, mTOR complex 1 inhibitors, mTOR complex 2 inhibitors, P-glycoprotein modulators, RNA polymerase modulators, TAT protein inhibitors, prolyl endopeptidase inhibitors, phospholipase A2 inhibitors, pharmacokinetic enhancers, HIV gene therapy, HIV vaccines, and anti-HIV peptides, or any combination thereof.

124. The compound for use according to any one of claims 119 to 123, wherein the 1, 2, 3, or 4 additional therapeutic agent is selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latent infection reactivators, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies, bispecific antibodies, and “antibody-like” therapeutic proteins, or any combination thereof.

125. The compound for use according to any one of claims 119 to 124, wherein the 1, 2, 3, or 4 additional therapeutic agent is selected from the group consisting of dolutegravir, cabotegravir, darunavir, bictegravir, el-sulfavirine, rilpivirine, abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemi-fumarate, tenofovir alafenamide, and tenofovir alafenamide hemi-fumarate, or pharmaceutically acceptable salts thereof.

126. The compound for use according to any one of claims 119 to 125, wherein the 1, 2, 3, or 4 additional therapeutic agent is selected from abacavir sulfate, bictegravir, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide, tenofovir alafenamide fumarate, and tenofovir alafenamide hemifumarate.

127. The compound for use according to any one of claims 119 to 126, wherein the 1, 2, 3, or 4 additional therapeutic agent is selected from tenofovir alafenamide, tenofovir alafenamide fumarate, and tenofovir alafenamide hemifumarate.

128. The compound for use according to any one of claims 119 to 124, wherein the 1, 2, 3, or 4 additional therapeutic agents are selected from bictegravir, emtricitabine, and GS-9131.

129. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 291】 A compound for use according to any one of claims 119 to 124, selected from pharmaceutically acceptable salts thereof.

130. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 292】 A compound for use according to any one of claims 119-124 and 129, selected from pharmaceutically acceptable salts thereof.

131. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 293】 A compound for use according to any one of claims 119-124, 129, and 130, or a pharmaceutically acceptable salt thereof.

132. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 294】 A compound for use according to any one of claims 119-124, 129, and 130, or a pharmaceutically acceptable salt thereof.

133. The compound for use according to any one of claims 117 to 132, wherein the patient is a human.

134. Use of a compound according to any one of claims 1 to 89 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 90 to 101, in the manufacture of a pharmaceutical.

135. Use of a compound according to any one of claims 1 to 89 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 90 to 101, in the manufacture of a pharmaceutical for treating or preventing human immunodeficiency virus (HIV) infection in a patient.

136. Use of a compound according to any one of claims 1 to 89 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition according to any one of claims 90 to 101, in the manufacture of a pharmaceutical for treating human immunodeficiency virus (HIV) infection in patients who have undergone severe treatment.

137. The use according to claim 135 or 136, wherein the pharmaceutical agent is administered together with one, two, three, or four additional therapeutic agents.

138. The use according to claim 137, wherein the 1, 2, 3, or 4 additional therapeutic agents are administered simultaneously with the pharmaceutical agent.

139. The use according to claim 137, wherein the pharmaceutical agent is combined with the 1, 2, 3, or 4 additional therapeutic agents in a unit dosage form for simultaneous administration.

140. The use according to claim 137, wherein the pharmaceutical agent and the 1, 2, 3, or 4 additional therapeutic agents are administered sequentially.

141. The aforementioned 1, 2, 3, or 4 additional therapeutic agents include combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latent infection reactivators, compounds targeting the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and "antibody-like" therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitors, and HIV vif gene modulator, vif dimerizing antagonist, HIV-1 virus infectivity factor inhibitor, TAT protein inhibitor, HIV-1 Nef modulator, Hck tyrosine kinase modulator, mixed lineage kinase-3 (MLK-3) inhibitor, HIV-1 splicing inhibitor, Rev protein inhibitor, integrin antagonist, nucleoprotein inhibitor, splicing factor modulator, COMM domain-containing protein 1 modulator, HIV ribonuclease H inhibitor, retrocycline modulator, CDK-9 inhibitor, dendritic cell ICAM-3 grabbing nonintegrin 1 inhibitor, HIV GAG protein inhibitor, HIV Use according to any one of claims 137 to 140, selected from POL protein inhibitors, complement factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin-dependent kinase inhibitors, proprotein converter PC9 stimulants, ATP-dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, and HIV vaccines, or any combination thereof.

142. The use according to any one of claims 137 to 140, wherein the 1, 2, 3, or 4 additional therapeutic agents are selected from HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, pharmacokinetic enhancers, and other drugs for treating HIV, or any combination thereof.

143. The use according to any one of claims 137 to 142, wherein the 1, 2, 3, or 4 additional therapeutic agents are selected from abacavir sulfate, bictegravir, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, emtricitabine, lamivudine, GS-9131, dolutegravir, and cabotegravir.

144. The use according to any one of claims 137 to 142, wherein the 1, 2, 3, or 4 additional therapeutic agents are selected from abacavir sulfate, bictegravir, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide, tenofovir alafenamide fumarate, and tenofovir alafenamide hemifumarate.

145. The use according to any one of claims 137 to 144, wherein the 1, 2, 3, or 4 additional therapeutic agents are selected from tenofovir alafenamide, tenofovir alafenamide fumarate, and tenofovir alafenamide hemifumarate.

146. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 295】 Or use according to any one of claims 137 to 142, selected from those pharmaceutically acceptable salts.

147. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 296】 Or use according to any one of claims 137-142 and 146, selected from those pharmaceutically acceptable salts.

148. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 297】 The use according to any one of claims 137-142, 146, and 147, or a pharmaceutically acceptable salt thereof.

149. The above 1, 2, 3, or 4 additional therapeutic agents, 【Chemistry 298】 The use according to any one of claims 137-142, 146, and 147, or a pharmaceutically acceptable salt thereof.

150. The use according to any one of claims 135 to 149, wherein the patient is a human being.

Images